
Pinned Tweet
Earlier today, Bloomberg reported that Optiver, one of the leading trading firms in the world, as well as a large university endowment fund have become strategic shareholders in Eden Block. We're honored to welcome these partners into Eden Block as we continue to aggressively scale our platform.
Eden Block is built on the belief that the most important systems of the next decade will emerge at the intersection of markets, software, and intelligence. This evolving amalgam of infrastructure will enable endless applications.
This view has not always been obvious. For a long time, much of what sits at this intersection felt early, fragmented, and difficult to categorize. Underlying teams, and the solutions they are working on did not fit neatly into any clear buckets that investors could easily underwrite. The infrastructure was incomplete, the applications immature and unclear. The demand signals were weak or indirect. In many cases, the most important work was happening below the level of visibility or interpretability that markets typically reward.
Over time, this direction has become more clear. Markets are becoming increasingly permissionless and programmable, and intelligent software, powered by compute, sits at the heart of their coordination and execution. Machine intelligence, once detached from broader economic activity, has become the beating heart of innovation, and the driver of most, if not all future inventions. Therefore, scaling and accelerating the capabilities of machine intelligence has become one of humanity's biggest missions. This expansion will occur across all layers of the stack: the infrastructure, the intelligence itself, and the applications it powers.
We've long held the belief that we've entered a point of no return, a point where all aspects of the world's dynamics converge on a free, permissionless market for innovation and advancement. In this market, technology loses all semblance of gravity. To put it simply, there's never been a better time in history to build things.
With the support of our new partners, we're doubling down on our mission to back the builders of the new internet. We meet relentless founders at the frontier, and build alongside them. With AI disrupting or empowering every single industry in the world, markets in particular are experiencing a dramatic shift. We're excited to bring the combined platforms of Eden Block and Optiver to accelerate the teams who are shaping the markets and technologies of tomorrow. We're confident that our combined efforts will foster new experimentation, and enable the dramatic shifts we're expecting to see across markets.
We're excited to reinforce our commitment to our founders, our conviction in Eden Block's mission, and the ecosystem we're building. We look forward to meeting you in the arena.
Founders: we're deploying.
Optiver Holding BV has taken an equity stake in crypto and artificial intelligence-focused venture capital firm Eden Block, as the two technologies continue to attract institutional backing. bloomberg.com/news/articles/…
Lior Messika retweeted
The drug class we are developing, Claromers, kill nearly all known germs (bacteria, viruses, fungi, and biofilms) with one simple devastating mechanism that has avoided microbial resistance for over 200 million years.
Claromers mimic a natural defense peptide in the human body called LL-37. Each Claromer molecule is very small, only dozens of atoms big - about 1/3 the size of the natural peptide. It is like a spear - a destructive end and a holding shaft or tail end. The shaft side is hydrophobic, which means it is water-avoiding and does not like to touch water. The other side - the pathogen destroyer - is highly positively charged (called “cationic” in science literature), like a powerful magnet that pulls toward anything negatively charged (called “anionic” in science).
Stanford bioengineering Assoc Prof Barron and colleagues wrote in a recent study of Claromers: “These amphipathic peptoids self-assembled in different ways, as determined by small-angle X-ray scattering; some adopt helical bundles, while others form core−shell ellipsoidal or worm-like micelles.” That means the groups form either short twisted bundles, like worms, or small oval shapes like a football. 🏈
The self-assembly into these nano structures I. the watery fluids of the body because the water-avoiding shaft-tails point inward toward each other , away from the water. The positive pathogen-killer ends stick outward like sharpened spears. The molecules stick together on their own into tight groups.
These groups attack like a three-dimensional Greek phalanx, a tight formation of soldiers. Like a football made of spears. The spears face out. Because each molecule is so tiny its mass is almost zero. When the positive killer ends feel the pull of the germ’s outer covering they accelerate from standing still to nearly the speed of light with almost no friction, like lightning bolt ⚡️ leaping towards the pathogen. The killer-football formation hits all at once the with huge kinetic energy and blows apart the outer membrane of the pathogen.
The germ cannot survive. It is destroyed in a microsecond.
Barron and colleagues also wrote: “While self-assembly correlated overall with antibacterial efficacy... Certain self-assembled morphologies seem better-suited for antibacterial activity.” The football 🏈 hits harder.
We choose the super effective oval shapes that mass the spears for the strongest hit.
Grok @bot by far the best agent harness I’ve ever used, and it’s not even close.
Grok Bot 0.77 looks INSANE 🔥
> Calls: your Bot can dial someone, sit on hold, press keys and get transferred while you watch a live transcript
> Messages on Mac: a setup screen under Connect Apps, still switched off
> Tailscale: Grok Bot can join your private tailnet once an admin approves it
> Payments: a screen to connect payment accounts and pick a default, on top of yesterday’s Vault
> Sharing: emails when someone shares a Bot with you, and invites need Premium or Ultra
There’s a really pronounced divide between people who are on the AI side of things and people who are on the biology side of things. Even among people working in AI, the divide persists based on where they’re focused.
The AI side, adherents of scaling laws and the bitter lesson, believe that AI getting better means AI being more capable of novel discoveries in medicine (that go beyond discovering new drugs in well understood targets or speeding up dry lab work etc).
The biology people think the idea of a bitter lesson in biology is kind of ridiculous and that regardless of AI’s capabilities it’s going to be at least 5-10 years until you could hope to reliably simulate human toxicology in silico (right now AI/ML can’t even reliably simulate in vivo studies like binding affinities or functional assays).
Even the most AI pilled of them, who will list all the areas that AI can reduce the time spent on various areas, don’t think the concept of AI discovering novel targets or generating new understanding of causal biology is realistic in the near term. Most, in fact, will readily characterize the assumption that even an “ASI” level model could find cures hidden in our current understanding (without expanding that understanding with significantly more biological data) as patently false.
This was a big part of why we wanted to experience it ourselves by using AI for a (very) small portion of what it can do in biology. It was both mind blowing and revealed some poignant insights into how different the problem of making AI better at something like coding is to the problems of biology.
Even if it unlocked the ability to generate new molecules at a stunning pace, its simulation (in silico) of binding only had 49% accuracy. And if we wanted to improve that, we’d need to feed it back the data from the lab - data that took about 30x as long to get as it took to generate the molecules. And these were tests in a test tube (turn of phrase), imagine how long it would take if we wanted to improve the model with data that required recruiting humans and monitoring their reactions.
Human biology is very complex, and adding a drug - especially a novel drug and doubly so for a novel drug acting on a novel mechanism - means mapping interactions that have nth-order-effects that we don’t have the data to predict. Virtual cells have made advancements enabled by AI, but the perturbations equate to a small fraction of the possible.
This is before you even get into curing disease, especially uniquely human diseases. Brain function involves cellular identities that are unique to humans, meaning animal studies are of little use.
How long does it take to understand what the side effects of chronic administration of a drug in humans are? AI can speed up analyzing the data, or designing the trial or even getting it approved…but it can’t make a 6 month trial complete in 3 months.
I think its important to point out that significant advancements can be made in AI that contribute to biology, while also being realistic about how much it speeds up something as complex as curing a specific cancer or diseases of the brain.
Lior Messika retweeted
Today was a clear wake-up call for the market. It’s apparent that most investors weren’t, and perhaps still aren’t, prepared for each of the big 5 (incl. SPCX) to potentially raise multiple hundreds of billions of equity/debt capital through 2030, and multiple trillions collectively. These investors also weren’t prepared for the capex growth to have no end in sight.
Ironically, many of the executives of these companies have been out in public clearly communicating their intention to keep spending very aggressively, with no plans to stop anytime soon.
And yet, for whatever reason, street estimates called for capex to slow dramatically into 2028 and basically plateau thereafter. The street modeled 50-60% capex growth across the big 5 in 2027 (which itself is low), and then MSD% growth annually. There is no good fundamental reason to model that unless you think companies spend less because the returns on the technology slow, or you think there are severe physical/power/financing constraints (though this would just result in slower growth, not the plateau that’s been modeled).
But it seems just as likely that out-year estimates simply defaulted to a plateau. Companies only guide a year out, and few on the sell-side are willing to model years of cash burn at this scale, so in their models, burn peaks in 2027 before FCF flips back positive in 2028 and scales from there. That path doesn’t require nearly as much capital issuance. To be clear, this would be a much happier and easier world for equity investors, who could go back to reaping the rewards instead of writing the checks. But for those who took the companies at their word and modeled continued elevated capex growth through the balance of this decade, these levels of issuance were a mathematical inevitability.
Yesterday’s filing from $META probably forced many to contemplate for the first time that each of these companies could actually burn and issue multiple hundreds of billions of dollars in the coming years. The credit markets have already shown signs of strain under the sheer magnitude of issuance, so more of this may need to be done through equity. That means there was also some front-running of eventual, unknown but likely material levels of dilution.
Equity markets don’t like being diluted, and they generally don’t like companies spending money at all. Especially not when the dollars get this big and when, rightly or wrongly, many still doubt the viability or magnitude of the returns, or at the very least don’t care to wait around to find out. Add in the crowding and leverage, along with a continued rise in oil on Middle East flare-ups, and you get a meaningful stock correction.
And so that’s what I believe the market priced in today: more burn, more issuance, more dilution, more leverage, more risk, more financing constraints (esp. for the most rate-exposed stuff, which got hit the worst today), along with some uptick in the chance this all falls apart.
This is going to sound perverse, but I think a day like today is very healthy. The companies are ambitious and the markets are stingy. And they will have to work with one another to get what they want. The companies want unprecedented capital to invest in what they believe is a re-platforming of the entire global infrastructure for an AI future, and the markets demand sufficient evidence that they’ll earn above the required return on the capital they lay out and the risk they take on. Ultimately, this forces the companies to be more disciplined and to show ROI as early and visibly as possible. That doesn’t mean they spend less, just that they have to prove the spend is working. I don’t think Zuck’s comment about monetizing Muse so much more rapidly than previous platforms was a coincidence. He knows what he needs, and he knows what he needs to show to get it.
So what now? Is AI a powerful enough driver to muscle its way through the fears being expressed by markets?
I think so. The big 5 may grow capex from >$1.3 trillion in 2027 to >$2.5 trillion in 2030, a ~25% CAGR. That implies a lot of paper, but in general, the hyperscalers can afford to pay higher rates, and there still seems to be demand from credit investors for it. At yesterday’s Robin Hood conference, execs at Diameter and HPS expressed a view that 7-8.5% yields on bonds from these companies are interesting. And I’d argue that’s for good reason: aside from SPCX, these companies generate massive operating cash flow and have largely benign net debt/EBITDA levels.
On the other hand, the more speculative companies that sit further out on the risk curve, pay higher spreads, and often don’t generate any cash at all will likely be forced to spend less. If you thought CRWV and NBIS would spend a combined ~$150-200 billion of capex in 2030 (vs. ~$60 billion in 2026), that might get cut in half because of financing constraints. But even a $100 billion reduction is only a 3-4% hit relative to the big 5’s 2030 capex, which, on net, is very manageable. That may be an issue for those companies, but it’s not enough to derail the ecosystem as a whole.
Ultimately, you have to believe there are attractive returns in AI, which I strongly believe are inflecting and wrote about here: xitter.cf/evergreencap3/status/2….
So even while things remain turbulent, the path still appears bright.
Some thoughts on AI ROI, which I believe is misunderstood and severely understated. TL;DR: AI ROI is inflecting for end customers (most important) and infra providers. Pure model provider ROI is less clear, but models will keep improving regardless, driving the industry forward.
Of all the debates on AI, the biggest and most persistent is around ROI. The problem is that the debate revolves around a single, inconsistently applied definition, when in reality there are three: 1) ROI for model providers, 2) ROI for model customers, and 3) ROI for infrastructure providers
While cooperative, #1 and #2 are fundamentally at odds with one another. All else equal, the higher the margin a model provider captures on the tokens it sells, the lower the margin the customer of those tokens captures on the work being done. This is driving enterprises to rationalize spend where they can: if a job can be done as effectively with a cheaper model, the ROI on that job is proportionally higher than if it were done with a more expensive model. That’s not 'bad' for AI. It just represents margin shifting from the provider to the customer.
Meanwhile, the ROI for infrastructure providers is a collective function of both. And while there are nuances around returns for individual infra providers depending on the concentration of and share between the model and customer cohorts, the reality is that infrastructure ROI overall benefits as long as demand for tokens keeps growing, regardless of the ongoing push-pull between model providers and customers.
In the last couple of months, we seem to be heading in a certain direction: aggregate model customer ROI is accelerating as customers benefit from the utility of increasingly intelligent tokens (and apps) at falling prices. This is evidenced by nearly all of the token-volume metrics across the industry, which continue to show growth and/or acceleration. Both the qualitative and quantitative data points on positive customer ROI are growing in concert, most recently with AWS CFO John Felton remarking that he studied AWS’ own token usage and found that, in general, more is better. And for those who still don’t believe in return on token spend, I implore you to model out the number of tokens needed to complete a job of your choice and measure the value of that job relative to the underlying cost of the tokens, with or without the model provider margin. Sure, there can always be waste. But when utilized properly, the returns on tokens are extraordinary, which is exactly what's driving continued volume growth.
We’ve subsequently seen this flow through to the cloud infrastructure providers, whose payback periods have compressed and whose returns have also increased, primarily as a function of rising rental prices for GPUs/accelerators. And as those returns have increased, so has demand for the underlying infrastructure, benefiting the AI supply chain at large.
So far, so good.
That leaves the model providers, where the biggest question really lies. The fact that inference gross margins can be so high is certainly positive in addition to being obvious: the prices at which tokens are sold are multiples higher than the miniscule cost of the underlying FLOPs needed to generate them. And again, the value of the work being done by the end customer is multiples higher than the token prices, so everybody wins. However, inference gross margins paint an incomplete picture, because token prices are primarily a function of model quality, which is primarily a function of training spend. That spend, in aggregate, is causing model providers to burn lots of cash. And because competition remains so intense, it’s unlikely in my view that any model provider can retain its inference margins without continued aggressive training spend. So the two go hand in hand and should be assessed together. While Anthropic’s reported positive FCF in 3Q was a nice surprise, I don’t expect it to continue, especially as OpenAI remains committed to investing aggressively and burning cash for the foreseeable future.
So that’s the predicament. The market is unsure what the long-term business and economic model of a 'lab' is, and rightly so. That raises the question: if the labs can’t make money, who’s going to fund the training, and how will the models keep getting better, which is the critical ingredient in continued AI adoption and end-customer ROI?
I see a few outcomes to this question:
Scenario 1: Concerns about model-provider economics prove overstated, and the market expands rapidly enough to accommodate multiple profitable frontier developers alongside a thriving open-source and open-weight ecosystem, supporting broad-based growth with attractive margins. This is probably the cleanest outcome which is why the market tends to like it so much. I still think this is the most likely path in the fullness of time, but it’s admittedly unclear. The mega-pilled RSI scenario also fits within this outcome, mainly in the sense that the investment pays off.
Scenario 2: Because of heightened competitive intensity and elevated training costs, the aggregate model provider ecosystem simply operates at maturity with razor-thin margins and very tight/minimal free cash flow generation, like other extremely competitive and/or commoditized industries. This is at least where we seem to be today, and where we will likely remain for some time.
Scenario 3: Financial pressure causes weaker participants to exit, merge, or scale back large training programs, eventually giving way to consolidation and reduced frontier training intensity, which allows the remaining players to expand margins. This seems both logical and likely to happen to some unknown degree, which would be positive for the value of the remaining players. Note that megacap tech hyperscalers, who collectively generate hundreds of billions in operating cash flow from their core businesses and are also training models, can continue to tap into that cash flow for ongoing training (ie GOOGL, META, and more recently NVDA). That will persist regardless of what happens with OpenAI or Anthropic.
Scenario 4: Frontier labs eventually convert into true public benefit corporations (in more than just name), owned and funded by a broad coalition of companies and the USG, all with incentives aligned toward the ongoing training and development of new models, effectively making the labs public utilities rather than private corporations. I do believe there is tremendous value in the IP at both OpenAI and Anthropic, and consequently see this as a far more likely outcome than either of them “going bust” and ceasing operations. While this may seem scarier to markets and in the headlines, the actual end result could be quite positive and well distributed across the entire AI ecosystem (rather than concentrated in the two labs). And at the very least, I believe there is strong merit in a pool of government-funded dollars for model development, much like the CHIPS and Science Act of 2022, which authorized $280 billion in federal funding and incentives. The US federal government spends >$7 trillion annually. Point being, there is both ample budget and precedent for the USG (and megacaps/others) to contribute to this national cause.
All in, some combination of these four outcomes should play out. And while some paths are smoother than others and there will be inevitable volatility and hiccups along the way, they all ultimately lead to positive ROI on AI spend: better models drive better end-customer returns, which drive better returns on infrastructure. That flywheel is already in motion (as evidenced by rising token volumes, GPU rental prices, and infra returns), and it’s much more sustainable than the market fears. It will take time to get from here to there, but the endgame appears to be quite positive, almost any way you slice it.
Interesting.
GPUs are aging like fine wine, with rental rates up across the board since January 1st
Approximate change YTD:
- H200: +160%
- B200: +120%
- RTX PRO 6000: +65%
- H100: +35%
Even the 6-year-old A100 rents for more than it did at the start of the year
Charts of the Week: a16z.news/p/charts-of-the-we…
Lior Messika retweeted
Honored to announce we have discovered the first cancer immunotherapy that fights aging !
It’s a peptide!
SenoMune-0257
longevity.technology/news/im…
Markets are not ready for AI-enabled biotech. Also, many boomer pharma/biotech investors won’t catch the generational teams building in this space.
SITUATION DETECTED: Warhound launched from stealth today with a $200M seed at a $1.2B valuation. Ben Lamm and Palmer Luckey are cloning gene-edited bio-enhanced dogs and equipping them with custom Anduril vests, goggles, and sensors for the military and law enforcement.
Gensyn CEO @benfielding warns that AI agents auditing other AI agents can be compromised too:
"We create swarms of AI agents that can do far more work than any human could. A human can’t follow along and check everything. One of the big counters is to say that agents can do the verification."
"But METR says those agents themselves can become corrupted by the training process, and you can’t trust any agent that’s auditing another agent. If you’ve trained a model in an auditable way, you can trust it."
"Any claim where the model is hiding its chain of thought falls away, because you have an exact log of everything that’s happened, and you can rerun every single step on any device."
"For national security, finance, pharma, health, insurance, it’s essential that they have models like these. If a regulator wanted to audit, they wouldn’t have to go off promises of the company."
@gensynai
This headshot is literally 7 years old, but excited to join DAS London alongside dear friends and industry goats.
Should be fun!
NEW: @edenblockvc Founder @lior_eth to speak at DAS London
Nov 10-11. London.
Be there: blockworks.com/event/digital…
Supabase is now fully available and open source thanks to Claude
i had 12 Claude agents running in parallel for 6 hours and i managed to reverse engineer @supabase
i'm making it available here so that you can save your tokens - 100% free & open-source:
github.com/supabase/supabase
Grok @bot beats Dot on most assistant-oriented dimensions for me. It notifies me within <1 second of new context coming in (confirmation emails, bookings, scheduling). Dot consistently comes in 3-20 mins later, often missing the window of usefulness.
Lior Messika retweeted
SCOOP: Fireworks AI is seeking to raise fresh funding at a valuation between $30 billion and $40 billion, a dramatic jump just months after the AI-infrastructure startup was valued at $17.5 billion.
businessinsider.com/firework…
Lior Messika retweeted
France has FREE health care, paid parental leave, paid family leave, FREE child care, FREE preschool, 5 weeks paid vacation, a 35 hour work week, generous unemployment and housing benefits, and heavily subsidized higher education.
Everything the left says they want AND THEY'RE STILL PROTESTING AND BURNING SHIT DOWN.

























